Spain Personalized Medicine Market

What is the Spain Personalized Medicine Market Size?

As per the survey report on Spain personalized medicine market, the market is expected to foresee a CAGR value of 8.4% during 2026-2036, and further generate a market size of USD 168.8 billion by the end of 2036. In 2025, the market size was value at USD 50.3 billion revenue.

• The Spain personalized medicine market’s growth is driven by investment by pharmaceutical industry.
• KDMI analyst’s growth analysis foresees high cost of therapies as restraint for Spain personalized medicine market.
• In the Spain personalized medicine market, product segment is playing significant role.

Spain Personalized Medicine Market Analysis

Personalized medicine is a healthcare model that customizes medical treatments, prevention, and diagnoses to the individual characteristics of each patient. It is one step ahead of traditional medicines, that fits all by using a person’s unique genetic, molecular, and environmental profile. The Spain personalized medicine market growth is driven by advancements in healthcare technology and personalized treatment approaches. According to the La Moncloa data, the Minister for Science, Innovation, and Universities, Diana Morant, has announced the country’s participation in the Genome of Europe (GoE) project. The project is funded with approximately 45 million euros, of which the Spain has contributed around 3 million euros in the investment drive. The project aims to create a reference of genome from around 100,000 people, of which 12,000 people for sequencing will be contributed by the Spain. Such initiatives support increased manufacturing of personalised medicines in the country.

Spain Personalised Medicine Market Growth Drivers and Restraints

Growth Drivers

• Investment by the Pharmaceutical Industry - Growing investment by the pharmaceutical industry is a key driver of the Spain personalized medicine market. Pharmaceutical companies are increasingly allocating resources toward the development of targeted therapies, precision diagnostics, and biomarker-based treatments that enable more individualized healthcare approaches. According to the laboratorios rubio, the pharmaceutical industry is highly dynamic, strategic, and innovation-driven in the country’s economy. The industry invested approximately 1.5 billion euros in R&D in 2024. Additionally, Spain is home to more than 134 innovative pharmaceutical companies, which represents 70.8% of prescription medicine sales in the national market. Additionally, collaborations between pharmaceutical firms, research institutions, and healthcare providers are strengthening Spain’s precision medicine ecosystem. Thus, driving and supporting significant expansion of Spain’s personalised medicine market.
• Growing Burden of Chronic Diseases - The rising prevalence of chronic diseases is another major factor driving the growth of the personalized medicine market in Spain. According to trading economics data, the Spanish population aged 65 and above was reported at 21.1% in 2024. The growing aging population is a key factor of rising chronic diseases burden in the country, which creates strong demand for personalised medicines. According to ELMUNDO America, the number cancer cases diagnosed in the country were approximately 296,103 cases in 2025. The most frequently diagnosed tumours were colon and rectum, followed by breast, lung, prostate, and urinary bladder. Such complex diseases often require tailored treatment approaches because patients can respond differently to the same therapy. Personalized medicine enables healthcare providers to use genetic, molecular, and clinical information to identify the most effective treatments for individual patients, improving outcomes while reducing unnecessary interventions and healthcare costs., thereby accelerating market adoption.

Restraints

• High cost of personalised therapies – One of the key restraints is that personalised medicines often rely on advanced genomic sequencing, biomarker testing, and targeted therapies, which requires higher upfront investment and more expensive than traditional treatment approaches. The high costs associated with these technologies further limits patient access and slowdowns overall market growth.
• Shortage of specialised healthcare professionals – The effective implementation of personalised medicines requires expertise in genomics, bioinformatics, molecular diagnostics, and precision therapeutics. The limited availability of healthcare professionals creates significant barrier for market expansion.

Spain Personalised Medicine Market Segmentation

Our experts at KD Market Insights have segmented the Spain personalised medicine market research report as:

Spain Personalised Medicine Market Competitive Landscape

Some of the significant participants who top the Spain personalised medicine market growth:

• Abbvie Inc
• GE Healthcare,Inc
• ARIEL Precision Medicine, Inc
• F. Hoffmann-La Roche Ltd
• Eli Lilly and Company
• Abbott Laboratories
• Takeda Pharmaceutical Company Ltd
• QIAGEN
• Aadi Bioscience, Inc
• Illumina, Inc